TiGenix – American Depositary Shares (NASDAQ:TIG) has earned a consensus broker rating score of 2.33 (Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. TiGenix – American Depositary Shares’ rating score has declined by 133% from 90 days ago as a result of various analysts’ ratings changes.
Brokers have set a one year consensus price target of $36.40 for the company, according to Zacks. Zacks has also given TiGenix – American Depositary Shares an industry rank of 196 out of 265 based on the ratings given to its competitors.
Several analysts have issued reports on TIG shares. Canaccord Genuity restated a “buy” rating and set a $50.00 price objective on shares of TiGenix – American Depositary Shares in a research note on Monday, December 18th. Zacks Investment Research upgraded TiGenix – American Depositary Shares from a “hold” rating to a “buy” rating and set a $26.00 price objective on the stock in a research note on Friday, January 5th. Finally, BidaskClub upgraded TiGenix – American Depositary Shares from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th.
Shares of TiGenix – American Depositary Shares (NASDAQ TIG) opened at $42.27 on Tuesday. TiGenix – American Depositary Shares has a one year low of $14.30 and a one year high of $42.73. The company has a quick ratio of 1.36, a current ratio of 1.37 and a debt-to-equity ratio of 0.10.
ILLEGAL ACTIVITY WARNING: “TiGenix – American Depositary Shares (TIG) Given $36.40 Consensus Price Target by Analysts” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/30/tigenix-american-depositary-shares-tig-given-36-40-consensus-price-target-by-analysts.html.
About TiGenix – American Depositary Shares
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.
Get a free copy of the Zacks research report on TiGenix – American Depositary Shares (TIG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TiGenix - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TiGenix - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.